PLx Pharma Inc. Showcases VAZALORE at The Annual Meeting of The Society for Cardiovascular Angiography and Interventions
SPARTA, N. J.,
Building Awareness of and Advocacy for VAZALORE®
Founded in 1978, SCAI is the primary professional association for invasive and interventional cardiologists, physicians who diagnose and treat cardiovascular disease and congenital and structural heart conditions through catheter-based procedures, such as angioplasty and stenting.1 Interventional cardiologists treat patients in acute hospital settings and initiate secondary prevention therapeutics, such as aspirin, which is foundational therapy for preventing another heart attack or clot-related stroke. Through the Company’s efforts to build awareness and advocacy for VAZALORE among healthcare professionals, including interventional cardiologists, it will prominently display VAZALORE during the SCAI annual meeting. The Company will also provide product samples and educational materials to the attending faculty, cardiologists, and fellows.
Article Published in Healio2 Examines VAZALORE as A Novel Aspirin Option
In the article titled, “Some Needs Unmet in Secondary CVD Prevention Despite Aspirin Use; New Agent May Have A Role,” author
1 SCAI website https://scai.org/about-us.
2 Healio is the parent company of Cardiology Today.
VAZALORE is an FDA-approved liquid-filled aspirin capsule, available in 81 mg and 325 mg doses. VAZALORE delivers aspirin differently from plain and enteric coated aspirin products. The special complex inside the capsule is designed for targeted release of aspirin, limiting its direct contact with the stomach. VAZALORE delivers fast, reliable absorption for pain relief plus the lifesaving benefits of aspirin. To learn more about VAZALORE, please visit www.vazalore.com.
Vice President, Investor Relations & Corporate Communications,
Founder & President,
Source: PLx Pharma Inc.